NCT05532631 Percutaneous Coronary RevascularizatiOn VERsus Coronary-Artery Bypass Grafting for Multivessel Disease in Patients With Left Ventricular Dysfunction (PROVERB)
| NCT ID | NCT05532631 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,040 participants |
| Start Date | 2023-03-16 |
| Primary Completion | 2030-07-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,040 participants in total. It began in 2023-03-16 with a primary completion date of 2030-07-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A short description, 5000 characters Ischemic cardiomyopathy related to coronary artery disease is currently the leading cause of heart failure. When it is responsible for heart failure, the coronary artery disease likely involves 2 or 3 vessels. Percutaneous coronary angioplasty, which is the other available technique for coronary revascularization, has never been evaluated in this indication. The results of retrospective registries studying the strategy for multivessel revascularization in patients with heart failure are inconsistent and no randomized study has been performed so far. Currently, ESC guidelines recommends to perform coronary-artery bypass grafting (IB) or percutaneous coronary intervention (IIa C) with the acknowledgement that percutaneous coronary intervention has never been properly evaluated in this setting. However, it has been previously demonstrated that left ventricle dysfunction significantly increases mortality and morbidity during and after cardiac surgery (3-10% mortality when LVEF is ≤30%). Moreover, the technical progresses in stent development and manufacturing have led to a dramatic decrease in the incidence of stent thrombosis and in-stent restenosis. Therefore, we hypothesize that percutaneous coronary angioplasty may be an attractive strategy for revascularization in patients with multi-vessel disease and left ventricle dysfunction, who are at high risk of surgical complication. Thus, we aim to test the hypothesis that percutaneous coronary intervention is non-inferior to coronary-artery bypass grafting for revascularization in patients with multivessel disease and left ventricle dysfunction. The main objective is to demonstrate that percutaneous coronary angioplasty is non-inferior to coronary-artery bypass grafting for multivessel revascularization in patients with left ventricular dysfunction on major cardiac and cerebrovascular events (MACCE). Method:A Prospective Randomized Open label, Blinded Endpoint, parallel-group, active controlled, non-inferiority, multicenter trial.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Left ventricle ejection fraction ≤35% measured by echocardiography, cardiac magnetic resonance imaging ventriculogram or gated Single Photon Emission Computed Tomography ventriculogram * Multivessel disease suitable for revascularization: * Three vessel disease * Two vessel disease involving left main or proximal left anterior descending artery * Clinical and anatomic eligibility for both percutaneous coronary intervention (PCI) and Coronary artery bypass grafting (CABG) as agreed to by the local Heart Team (interventionalist determines PCI appropriateness and eligibility; cardiac surgeon determines surgical appropriateness and eligibility) * Ability to sign informed consent and comply with all study procedures, including follow-up for at least two years * Affiliation to health insurance Exclusion Criteria: * Prior: * PCI of any coronary artery lesions within 6 months prior to randomization * CABG at any time prior to randomization * Ongoing cardiogenic shock at the time of coronary angiogram (SBP\< 90 mmHg with clinical signs of low output or patients requiring inotropic agents) * Contra indication for PCI or CABG determined by the heart team * Indication for another cardiac surgery (i.e. valvular surgery, aortic repair…) if CABG is performed * ST elevation myocardial infarction \< 30 days * Non-cardiac illness with a life expectancy of less than 24 months * Current participation in other investigational drug or device studies * Women who are pregnant or nursing * Females of childbearing potential without effective method of birth control * Patients who are under tutorship or curatorship * Patient on AME (state medical aid)
Contact & Investigator
Akim SOUAG
STUDY CHAIR
Assistance Publique Hôpitaux de Paris- CHU Henri-Mondor
Frequently Asked Questions
Who can join the NCT05532631 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05532631 currently recruiting?
Yes, NCT05532631 is actively recruiting participants. Contact the research team at romain.gallet@aphp.fr for enrollment information.
Where is the NCT05532631 trial being conducted?
This trial is being conducted at Créteil, France.
Who is sponsoring the NCT05532631 clinical trial?
NCT05532631 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Akim SOUAG at Assistance Publique Hôpitaux de Paris- CHU Henri-Mondor. The trial plans to enroll 1,040 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.